AstraZeneca on Monday reported data from a new combination study showing a combination of targeted and immunotherapies can benefit patients with certain kinds of liver cancer.
AstraZeneca presented at ASCO 2026 phase trial data showing a triplet regimen — one targeted therapy plus two immunotherapies — improves outcomes in a subset of liver cancer patients. For biopharma-adjacent tech and health AI teams, the combo approach signals that oncology pipelines are shifting toward multi-modal protocols, increasing demand for biomarker-driven patient stratification and real-world data infrastructure.
AstraZeneca at #ASCO2026 (Karen Weintraub for Endpoints News)
June 1, 2026 08:00 AM EDT
AstraZeneca's triplet combo succeeds in some liver cancer patients
Max Gelman
CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain …
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial - AstraZeneca (NYSE:AZN)
Immunotherapy combination may improve outcomes in unresectable liver cancer
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Akeso, Summit drug extends survival in closely watched lung cancer trial
Cancro fegato, nuova combinazione di farmaci migliora la sopravvivenza - Il Quotidiano del Sud
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
Cancro fegato, nuova combinazione di farmaci migliora la sopravvivenza
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3…
AstraZeneca's EMERALD-3 trial shows improved progression-free survival with STRIDE, lenvatinib and TACE in liver cancer.
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at…
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer…
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a…
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
